Abstract
Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism–jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parafibromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parafibromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arnold A, Motokura T, Bloom T, Kronenberg H, Ruderman J, Juppner H and Kim HG . (1991). Cold Spring Harb. Symp. Quant. Biol., 56, 93–97.
Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y and Saucier K . (2002). J. Bone Miner. Res., 17 (Suppl 2), N30–N36.
Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath III H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C and Hobbs MR . (2002). Nat. Genet., 32, 676–680.
Cavaco BM, Barros L, Pannett AAJ, Ruas L, Carvalheiro M, Ruas MMA, Krausz T, Santos MA, Sobrinho LG, Leite V and Thakker RV . (2001). QJM, 94, 213–222.
Dinnen JS, Greenwoood RH, Jones JH, Walker DA and Williams ED . (1977). J. Clin. Pathol., 30, 966–975.
Elledge SJ and Amon A . (2002). Cancer Cell, 1, 129–132.
Firat D and Stutzman L . (1968). Am. J. Med., 44, 421–429.
Fujikawa M, Okamura K, Sato K, Mizokami T, Tamaki K, Yanagida T and Fujishima M . (1998). Eur. J. Endocrinol., 138, 557–561.
Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H and Teh BT . (2003). J. Med. Genet., 40, 657–663.
Hsi ED, Zukerberg LR, Yang WI and Arnold A . (1996). J. Clin. Endocrinol. Metab., 81, 1736–1739.
Inoue H, Miki H, Oshimo K, Tanaka K, Monden Y, Yamamoto A, Kagawa S, Sano N, Hayashi E and Nagayama M . (1995). Clin. Endocrinol. (Oxford)., 43, 225–229.
Jackson CE . (1958). Ann. Intern. Med., 49, 829–836.
Jackson CE, Norum RA, Boyd SB, Talpos GB, Wilson SD, Taggart RT and Mallette LE . (1990). Surgery, 108, 1006–1012.
Kakinuma A, Morimoto I, Nakano Y, Fujimoto R, Ishida O, Okada Y, Inokuchi N, Fujihira T and Eto S . (1994). Intern. Med., 33, 123–126.
Kennett S and Pollick H . (1971). Oral. Surg. Oral Med. Oral Pathol., 31, 502–510.
Lim PS, Jenson AB, Cowsert L, Nakai Y, Lim LY, Jin XW and Sundberg JP . (1990). J. Infect. Dis., 162, 1263–1269.
Mallette LE, Malini S, Rappaport MP and Kirkland JL . (1987). Ann. Intern. Med., 107, 54–60.
Marx SJ . (2002). The Genetic Basis of Human Cancer Kinzler KW (ed). McGraw-Hill: New York, pp. 475–500.
Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ and Arnold A . (1999). Endocr. Rev., 20, 501–534.
Rosen IB and Palmer JA . (1981). Am. J. Surg., 142, 494–498.
Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C and Arnold A . (2003). N. Engl. J. Med., 349, 1722–1729.
Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN and Marx SJ . (2002). Medicine (Baltimore)., 81, 1–26.
Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD and Marx SJ . (2004). J. Clin. Endocrinol. Metab., 89, 96–102.
Streeten EA, Weinstein LS, Norton JA, Mulvihill JJ, White BJ, Friedman E, Jaffe G, Brandi ML, Stewart K, Zimering MB, Spiegel AM, Aurbach GD and Marx SJ . (1992). J. Clin. Endocrinol. Metab., 75, 362–366.
Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, Leppert MF and Heath III H . (1995). Am. J. Hum. Genet., 56, 944–950.
Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, Yap A, Epstein M, Heath III H, Cameron D and Larsson C . (1996). J. Clin. Endocrinol. Metab., 81, 4204–4211.
Teh BT, Farnebo F, Twigg S, Höög A, Kytölä S, Korpi-Hyövälti E, Wong FK, Nordenström J, Grimelius L, Sandelin K, Robinson B, Farnebo LO and Larsson C . (1998). J. Clin. Endocrinol. Metab., 83, 2114–2120.
Vasef MA, Brynes RK, Sturm M, Bromley C and Robinson RA . (1999). Mod. Pathol., 12, 412–416.
Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG and Larsson C . (2004). J. Med. Genet., 41, e32.
Visset J, Letessier E, Perchenet AS, Fiche M, Hamy A and Paineau J . (1992). Chirurgie., 118, 223–228.
Warnakulasuriya S, Markwell BD and Williams DM . (1985). Oral Surg. Oral Med. Oral Pathol., 59, 269–274.
Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, Peters TJ and Larsson C . (1993). J. Clin. Endocrinol. Metab., 77, 1485–1489.
Yoshimoto K, Endo H, Tsuyuguchi M, Tanaka C, Kimura T, Iwahana H, Kato G, Sano T and Itakura M . (1998). Clin. Endocrinol. (Oxford)., 48, 67–72.
Acknowledgements
We thank the clinical fellows, Craig Cochran, and the nursing staff of the Clinical Center 8-West patient care unit, our colleagues Dr Monica Skarulis, Lee S Weinstein, and Allen M Spiegel of the NIDDK, and our surgical oncology colleagues Drs Steven K Libutti, James Pingpank, H Richard Alexander and Dao Nguyen of the NCI for their support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woodard, G., Lin, L., Zhang, JH. et al. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24, 1272–1276 (2005). https://doi.org/10.1038/sj.onc.1208274
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208274
Keywords
This article is cited by
-
A two-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family: clinical presentations, pathological characteristics and genetic analysis: a case report
Diagnostic Pathology (2022)
-
A novel long-range deletion spanning CDC73 and upper-stream genes discovered in a kindred of familial primary hyperparathyroidism
Endocrine (2022)
-
Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice
Endocrine Pathology (2021)
-
Current concepts in parathyroid carcinoma: a single Centre experience
BMC Endocrine Disorders (2019)
-
Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center
Modern Pathology (2019)